Surface Oncology (DB:QSOA) - Cours de l'action, nouvelles et analyse

QSOA Aperçu des actions

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. Plus de détails

QSOA analyse fondamentale
Score flocon de neige
Évaluation	2/6
Croissance future	0/6
Performances passées	0/6
Santé financière	4/6
Dividendes	0/6

Analyse des risques

Cours de l'action très volatil au cours des 3 derniers mois

A moins d'un an de piste de trésorerie

Réalise moins d'un million de dollars de revenus ( $0 )

Les actionnaires ont été dilués au cours de l'année écoulée

+ 2 plus de risques

Surface Oncology, Inc. Concurrents

4SC

DB:VSC

€51.9m

Medigene

XTRA:MDG1

€20.6m

Heidelberg Pharma

XTRA:HPHA

€106.7m

2invest

XTRA:2INV

€63.2m

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Surface Oncology
Historique des cours de bourse
Prix actuel de l'action	US$0.99
Plus haut sur 52 semaines	US$1.41
Plus bas sur 52 semaines	US$0.52
Bêta	1.75
1Variation sur 1 mois	16.19%
Variation sur 3 mois	36.16%
Variation sur 1 an	-27.10%
3Variation sur 3 ans	-82.41%
Variation sur 5 ans	-88.77%
Évolution depuis l'introduction en bourse	-90.74%

Nouvelles et mises à jour récentes

Recent updates

Rendement pour les actionnaires

	QSOA	DE Biotechs	DE Marché
7D	-0.7%	0.8%	0.8%
1Y	-27.1%	-18.3%	8.6%

Rendement vs Industrie: QSOA a sous-performé le secteur German Biotechs qui a rapporté -18.3 % au cours de l'année écoulée.

Rendement vs marché: QSOA a sous-performé le marché German qui a rapporté 8.6 % au cours de l'année écoulée.

Volatilité des prix

Is QSOA's price volatile compared to industry and market?
QSOA volatility
QSOA Average Weekly Movement	12.0%
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Cours de l'action stable: Le cours de l'action de QSOA a été volatil au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de QSOA ( 12% ) est restée stable au cours de l'année écoulée, mais reste supérieure à 75 % des actions de German.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
2014	35	Rob Ross	www.surfaceoncology.com

Surface Oncology, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de Surface Oncology se comparent-ils à sa capitalisation boursière ?
QSOA statistiques fondamentales
Capitalisation boursière	€60.83m
Bénéfices(TTM)	-€86.46m
Recettes(TTM)	n/a

0.0x

Ratio P/S

-0.7x

Ratio P/E

Le site QSOA est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
QSOA compte de résultat (TTM)
Recettes	US$0
Coût des recettes	US$67.00m
Marge brute	-US$67.00m
Autres dépenses	US$25.50m
Les revenus	-US$92.50m

Derniers bénéfices déclarés

Jun 30, 2023

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	-1.52
Marge brute	0.00%
Marge bénéficiaire nette	0.00%
Ratio dettes/capitaux propres	0%

Quelles ont été les performances à long terme de QSOA?

Voir les performances historiques et les comparaisons

QSOA Aperçu des actions

Analyse des risques

Surface Oncology, Inc. Concurrents

DB:VSC

€51.9m

XTRA:MDG1

€20.6m

XTRA:HPHA

€106.7m

XTRA:2INV

€63.2m

Historique des prix et performances

Nouvelles et mises à jour récentes

Surface Oncology, Inc. Files Form 15

Coherus BioSciences, Inc. (NasdaqGM:CHRS) completed the acquisition of Surface Oncology, Inc. (NasdaqGM : SURF) from Novartis Institutes for BioMedical Research, Inc., Atlas Venture Fund IX, L.P., managed by Atlas Venture L.P., ARK Investment Management LLC, EcoR1 Capital, LLC and others.

Nasdaq Approves Surface Oncology, Inc.'s Common Stock Transfer the Listing from the Nasdaq Global Market to the Nasdaq Capital Market

Coherus BioSciences, Inc. (NasdaqGM:CHRS) entered into a definitive merger agreement to acquire Surface Oncology, Inc. (NasdaqGM : SURF) for transaction value of $65 million.

Full year 2022 earnings released: US$1.14 loss per share (vs US$1.77 loss in FY 2021)

Surface Oncology Receives A Deficiency Letter from the Nasdaq Regarding Minimum Bid Price Requirement

Recent updates

Surface Oncology, Inc. Files Form 15

Coherus BioSciences, Inc. (NasdaqGM:CHRS) completed the acquisition of Surface Oncology, Inc. (NasdaqGM : SURF) from Novartis Institutes for BioMedical Research, Inc., Atlas Venture Fund IX, L.P., managed by Atlas Venture L.P., ARK Investment Management LLC, EcoR1 Capital, LLC and others.

Nasdaq Approves Surface Oncology, Inc.'s Common Stock Transfer the Listing from the Nasdaq Global Market to the Nasdaq Capital Market

Coherus BioSciences, Inc. (NasdaqGM:CHRS) entered into a definitive merger agreement to acquire Surface Oncology, Inc. (NasdaqGM : SURF) for transaction value of $65 million.

Full year 2022 earnings released: US$1.14 loss per share (vs US$1.77 loss in FY 2021)

Surface Oncology Receives A Deficiency Letter from the Nasdaq Regarding Minimum Bid Price Requirement

Vaccinex, Inc. Announces First Patient Dosed with Anti-Ccr8 Antibody Licensed to Surface Oncology

Surface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors

Third quarter 2022 earnings released: US$0.39 loss per share (vs US$0.44 loss in 3Q 2021)

Surface Oncology to Present Preclinical Data Highlighting the IL-27 Gene Expression Signature in Treatment-Resistant Cancers at the 10th Annual International Cytokine and Interferon Society Meeting

Second quarter 2022 earnings released: US$0.46 loss per share (vs US$0.43 loss in 2Q 2021)

Surface Oncology Appoints Carsten Brunn to Board of Directors

Surface Oncology, Inc. Announces Publication of New Study Demonstrating the Role of the IL-27 Pathway in Hepatocellular Carcinoma

Surface Oncology, Inc. Presents New SRF388 Clinical Data At 2022 American Society of Clinical Oncology Annual Meeting

First quarter 2022 earnings released: EPS: US$0.13 (vs US$0.37 loss in 1Q 2021)

Surface Oncology, Inc. to Present Clinical Update on SRF388 at American Society of Clinical Oncology Annual Meeting

Surface Oncology, Inc. Announces Initiation of Phase 2 Studies Evaluating SRF388 in Patients with Hepatocellular Carcinoma and Non-Small-Cell Lung Cancer

Surface Oncology Achieves $30 Million Milestone with First Patient Dosed in GlaxoSmithKline Phase 1 Study

Surface Oncology Announces Stepping Down of Geoffrey McDonough from the Board of Directors

Surface Oncology Announces Stepping Down of Geoffrey McDonough from the Board of Directors

Surface Oncology to Present New Clinical Data from Ongoing SRF617 Phase 1 Trial at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021

Surface Oncology Announces FDA Clearance of IND Application for GSK4381562

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Surface Oncology Announces the Presentation of New Data from the Ongoing Phase 1 Studies of SRF388 and SRF617

Investor sentiment improved over the past week

First quarter 2021 earnings released: US$0.37 loss per share (vs US$0.81 profit in 1Q 2020)

Surface Oncology, Inc. (NasdaqGM:SURF) acquired worldwide, exclusive, sublicensable license of Vaccinex, Inc. (NasdaqCM:VCNX).

Investor sentiment deteriorated over the past week

Surface Oncology Collaborates with Merck on Immuno-Oncology Study Evaluating SRF388, Targeting IL-27, in Combination with KEYTRUDA in Patients with Solid Tumors

Revenue beats expectations

Full year 2020 earnings released: EPS US$1.67 (vs US$1.97 loss in FY 2019)

New 90-day low: €5.95

Surface Oncology, Inc. Announces Resignation of Daniel S. Lynch as Member and Chairman, Effective April 1, 2021

Surface Oncology, Inc. Announces Executive Changes, Effective April 1, 2021

New 90-day high: €9.20

Surface Oncology Announces Exclusive License Agreement with GSK for Novel Immunotherapy Program

New 90-day high: €8.75

Surface Oncology, Inc. Announces FDA Fast Track Designation Granted by U.S. Food and Drug Administration for SRF388 to Treat Liver Cancer

Revenue in line with expectations

Surface Oncology to Present Srf388 and Srf114 Preclinical Data At the Upcoming Society for Immunotherapy for Cancer 2020 Virtual Conference

Surface Oncology, Inc. Announces Preclinical Data on SRF388

New 90-day high: €6.05

New 90-day high - €5.95

Earnings released

Surface Oncology, Inc.(NasdaqGM:SURF) dropped from Russell Microcap Value Index

Rendement pour les actionnaires

Volatilité des prix

À propos de l'entreprise

Surface Oncology, Inc. Résumé des fondamentaux

0.0x

-0.7x

Bénéfices et recettes